Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nicoya Lifesciences

Explore full profile

A biotech company using nanotechnology to make scientific instruments more affordable and user-friendly, aiding scientists in their work

Kitchener, CanadaFounded 2012Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2021
Headcount 100–500 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Nicoya Lifesciences and the history behind them.

About Nicoya Lifesciences

Nicoya is a Canadian biotechnology company dedicated to improving human life by empowering scientists with advanced, user-friendly tools. Founded in 2012 by Ryan Denomme, Nicoya's mission is to leverage nanotechnology to enhance the affordability and ease of use of scientific instruments, making cutting-edge research more accessible to the scientific community.

Read full description

At the core of Nicoya's offerings is its innovative line of scientific instruments designed to streamline and accelerate research processes. By focusing on nanotechnology, Nicoya develops instruments that are not only highly precise and reliable but also cost-effective and easy to use. This commitment to accessibility ensures that researchers across various disciplines can benefit from state-of-the-art technology without the barriers of high costs or complex operations.

One of Nicoya's flagship products is the OpenSPR, a benchtop Surface Plasmon Resonance (SPR) instrument. SPR is a powerful technique used to study molecular interactions in real-time, providing valuable insights into biological processes and drug discovery. The OpenSPR is designed to be compact, affordable, and user-friendly, making it an ideal tool for academic labs, biotech companies, and pharmaceutical research facilities. By democratizing access to SPR technology, Nicoya enables more scientists to conduct high-quality research and drive innovation in their fields.

In addition to its hardware offerings, Nicoya provides comprehensive software solutions that complement its instruments. These software tools offer advanced data analysis and visualization capabilities, allowing researchers to interpret their results more effectively and gain deeper insights into their studies. Nicoya's software is designed to be intuitive and easy to use, ensuring that scientists can focus on their research rather than navigating complex software interfaces.

Nicoya is also committed to fostering a collaborative and supportive scientific community. The company offers educational resources, training programs, and customer support to help researchers maximize the potential of their instruments and achieve their research goals. By providing ongoing support and engagement, Nicoya ensures that scientists have the tools and knowledge they need to succeed.

With a team of experienced scientists, engineers, and industry professionals, Nicoya is dedicated to continuous innovation and improvement. The company invests in research and development to stay at the forefront of nanotechnology and scientific instrumentation, ensuring that its products remain cutting-edge and effective in addressing the evolving needs of the scientific community.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2012
Headquarters
Kitchener, Canada
Employees
123
Open positions
None listed
Dealroom signal
68.1/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, Microfluidics, Spinout, Tech for Biotech and Pharma, Hard Tech
Technology
Deep Tech, Nanotech, IoT InternetOfThings
Business model
Manufacturing
Client focus
b2b
Investment activity
2 companies, latest Jun 2025
Capital deployed
Preferred round
ACQUISITION

Latest news

Press, funding announcements and product moves mentioning Nicoya Lifesciences.

See all news

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AEquity / VC Dec 2021 $15M $59M Export Development Canada · MaRS Investment Accelerator Fund · Agilent · Garage Capital
GRANTOther financing Jun 2020 $300K National Research Council Canada
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Nicoya Lifesciences website traffic

Latest recorded traffic for Nicoya Lifesciences is 11K monthly website visits, down 8.3% over the last three months. Nicoya Lifesciences's team declined 0.8% over the past year.

Latest monthly visits11K 3-month web change-8.3% 1-year team growth-0.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • MaRS Investment Accelerator Fund
  • University of Waterloo Student Venture Fund
  • National Research Council Canada

Series A13 investors entered at this stage

  • University of Waterloo
  • Ripple Ventures
  • Laurier Start-up Fund
  • BDC Capital
  • Innovation Grade Capital
  • Angel One Network
  • NorthSpring Capital Partners
  • Maple Leaf Angels
  • FedDev Ontario
  • Whitecap Venture Partners
  • Export Development Canada
  • Agilent
  • Garage Capital

Other known investors2 additional known investors

  • Graphite Ventures
  • Velocity
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇦 Canada75%
🇺🇸 United States16.7%
🇬🇧 United Kingdom8.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nicoya Lifesciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nicoya Lifesciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.